Klivira
Request demo

Streamlining Aetna Soliris Prior Authorization

Navigating Aetna Soliris prior authorization efficiently is crucial for patient access to this high-cost specialty medication. Klivira streamlines the complex requirements, reducing administrative burden and accelerating approval times.

For revenue cycle directors and prior authorization coordinators, managing specialty drug PAs like Soliris requires precise execution across multiple payer channels. Understanding Aetna's specific submission protocols, policy criteria, and turnaround expectations is paramount to minimizing denials and ensuring timely treatment for patients with conditions such as paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).

Aetna Soliris Prior Authorization Submission Channels

Soliris, often managed under the medical benefit, typically routes through Aetna's specialty-pharmacy-management workflows. For medical benefit precertification, providers primarily use the Availity provider portal or submit X12 278 transactions via clearinghouses. Pharmacy benefit requests, if applicable for Soliris, are processed through CVS Caremark, Aetna's PBM, leveraging ePA partners like CoverMyMeds or Surescripts for retail, or CVS Caremark's direct portal for mail-order.

Understanding Aetna's Medical Necessity Criteria for Soliris

Aetna publishes its medical-necessity criteria for specialty drugs, including Soliris, within its Clinical Policy Bulletins (CPBs) library. Each CPB is versioned and provides the canonical identifier for policy citations. These CPBs specify the clinical indications, diagnostic requirements, and potential step-therapy protocols necessary for approval.

Accelerating Soliris PA Turnaround Times with Aetna

Aetna's PA turnaround times for Soliris are influenced by state-specific regulations and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed care plans (Aetna Better Health), CMS-0057-F mandates 72-hour standard and 24-hour expedited decision timeframes. Klivira's platform helps providers meet these deadlines by automating documentation and submission.

Common Denial Reasons and Appeal Pathways for Soliris with Aetna

Denials for Soliris prior authorizations often stem from insufficient documentation of medical necessity, lack of adherence to step-therapy requirements, or off-label use without compendium support. Aetna communicates denial reasons via X12 835/277 transactions or portal updates, utilizing CARC and RARC codes. The appeal pathway typically involves reconsideration, peer-to-peer review, and formal appeals, with expedited options for urgent cases.

Key Considerations for Soliris PA with Aetna

  • Verify Soliris's current benefit assignment (medical vs. pharmacy) with Aetna.
  • Consult the latest Aetna Clinical Policy Bulletin (CPB) for specific medical necessity criteria and step-therapy requirements.
  • Utilize Availity for medical benefit submissions or appropriate ePA channels for pharmacy benefit.
  • Ensure comprehensive clinical documentation supporting the diagnosis and treatment plan.
  • Be prepared for potential peer-to-peer review in case of initial denial.
  • Understand state-specific turnaround time mandates applicable to the patient's plan.

Klivira's Role in Optimizing Aetna Soliris PA

Klivira integrates directly with EMRs and Aetna's submission channels, including Availity and X12 278, to automate the prior authorization workflow for specialty drugs like Soliris. Our platform streamlines documentation gathering, ensures adherence to specific Aetna CPB requirements, and facilitates timely submissions, significantly reducing manual effort and improving approval rates.

Frequently asked questions

Which Aetna submission channels are used for Soliris prior authorization?

Soliris prior authorizations typically route through Aetna's specialty-pharmacy-management workflow under the medical benefit, primarily via the Availity provider portal or X12 278 transactions. If Soliris were to fall under the pharmacy benefit, requests would be managed by CVS Caremark, utilizing ePA partners like CoverMyMeds or Surescripts.

Where can I find Aetna's medical necessity criteria for Soliris?

Aetna's medical necessity criteria for Soliris are published in their public Clinical Policy Bulletins (CPBs) library. You should always reference the specific CPB number and its most recent review date to ensure compliance with the current policy requirements, including any step-therapy protocols.

What are the typical turnaround times for Soliris PA decisions with Aetna?

Aetna's turnaround times for Soliris PA decisions vary by line of business and state regulations. For Medicare Advantage and Medicaid managed care plans, CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions. Commercial plans are subject to state-specific rules and NCQA UM accreditation standards, which historically set 15 calendar days for non-urgent pre-service decisions.

What are common reasons for Aetna to deny Soliris prior authorizations?

Common denial reasons for Soliris prior authorizations by Aetna include insufficient documentation of medical necessity, failure to meet specific clinical criteria outlined in the CPB, non-adherence to required step-therapy protocols, or off-label use without adequate compendium support. Denials are communicated with standard CARC and RARC codes.

Does Aetna support electronic prior authorization (ePA) for Soliris?

Aetna supports ePA for pharmacy benefit drugs through partners like CoverMyMeds and Surescripts. For medical benefit specialty drugs like Soliris, electronic submissions are primarily handled via the Availity portal or X12 278 transactions. Klivira integrates with these electronic channels to streamline the submission process.

Related coverage

Other soliris prior authorization by payer

Other soliris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo